News

Pilot test kit takes Proteomics step closer to sales – The West Australian

The pilot batch was produced primarily for quality control and regulatory testing. However, some components are expected to form inventory for initial sales.

Type 2 diabetes, for which PromarkerD is based, accounts for about 85 per cent of all diabetes. One-third of Type 2 diabetes sufferers have chronic kidney problems, the leading cause of end-stage renal disease.

International Diabetes Federation has estimated one in 11 adults has diabetes and the number is expected to grow to one in 10 by 2040. By then, the federation estimates diabetes-related health expenditure will exceed US$802 billion.

Article: Pilot test kit takes Proteomics step closer to sales

Subscribe
  • This field is for validation purposes and should be left unchanged.